PRKDC and B-cell chronic lymphocytic leukemia: In combination with radiotherapy, phase I clinical trials (NCT02516813 and NCT02316197) of a DNA-PK inhibitor MSC2490484A in advanced solid tumours or chronic lymphocytic leukaemia are being studied.